Back

Nature-AGT: Using Causal AI to estimate the optimal timing of lowering SBP with an siRNA directed against angiotensinogen to reduce the lifetime risk of cardiovascular events

31 August 2024 (08:15 - 08:27)
Organised by: Logo
Congress Presentation Part of: Highlighted registries, observational, and other studies Prevention ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Brian A Ference

University of Cambridge, Cambridge (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
Thirty-year cardiovascular outcomes in women based on C-reactive protein, LDL cholesterol, and lipoprotein(a)
Doctor P. Ridker (Boston, US)
Slides Video
Presentation thumbnail
Economic Toll of Cardiovascular Disease on Healthcare and Mortality in 50 ESC member countries
Doctor R. Luengo-Fernandez (Oxford, GB)
Slides Video
Presentation thumbnail
Incidental and progressive tobacco smoking from childhood through young adulthood with premature structural and functional cardiac damage in 1931 children: A 14-Year Longitudinal Study
Professor A. Agbaje (Kuopio, FI)
Slides Video
Presentation thumbnail
Global Pretest probability study of coronary artery disease
Doctor L. Baskaran (Singapore, SG)
Slides Video
Presentation thumbnail
Incremental value of cardiac myosin binding protein C to high-sensitivity cardiac troponin for the early diagnosis of acute myocardial infarction
Doctor P. Lopez Ayala (Basel, CH)
Slides Video

Access the full session

Session thumbnail
Highlighted registries, observational, and other studies
Video

The Event

Event poster

ESC Congress 2024

31 August 2024 08:15 CET
You may be interested in
thumbnail
Congress Presentation
Duration of blood pressure treatment and risk of major cardiovascular events
thumbnail
Congress Session
Late-Breaking Clinical Science: new treatments and biomarkers in hypertension
thumbnail
Congress Presentation
Benefit-harm trade-offs of intensive blood pressure control on cardiovascular and renal outcomes: an individual participant data analysis of six pivotal randomized controlled trials.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources